Status:

COMPLETED

Effect of Aliskiren and Hydrochlorothiazide on Kidney Oxygenation in Patients With Hypertension

Lead Sponsor:

Centre Hospitalier Universitaire Vaudois

Conditions:

Hypertension

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

The goal of this project is to evaluate the chronic effect (8 weeks) of RASILEZ 300mg (aliskiren) on renal tissue oxygenation in patients with stage 1-2 hypertension, and to compare the chronic effect...

Detailed Description

36 patients with arterial hypertension stage 1-2 (blood pressure: 140/90 and 180/110 mm Hg) will be included in this study and randomized to two groups of 18 patients each: one group will receive RASI...

Eligibility Criteria

Inclusion

  • Tolerance to study drugs
  • Age \> 18 years
  • Arteria hypertension stage 1-2 (blood pressure: 140/90 and 180/110 mm Hg)
  • Normal renal function
  • Availability to give informed consent

Exclusion

  • Intolerance to study drugs
  • Renal artery stenosis
  • Hyperkalaemia \> 5.0 mmol/l
  • Contra-indications to the use of PAH, inulin or Lithium
  • Asthma
  • Pychiatric illness
  • No estimated easy vascular venous access for placement of two peripherical venous catheters in forearms
  • Contra-indication to MRI-imaging: Claustrophobia or Pacemaker or other implanted metal device

Key Trial Info

Start Date :

October 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2014

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT01519635

Start Date

October 1 2011

End Date

October 1 2014

Last Update

March 17 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Centre Hospitalier Universitaire Vaudois

Lausanne, Canton of Vaud, Switzerland, 1004